Dicerna bags $25M Series B for next-gen RNAi work

Dicerna Pharmaceuticals has landed a $25 million Series B to fuel its work on a new and improved slate of gene-silencing therapies. Still in the preclinical stage, the Watertown, MA-based developer is focusing on solid tumors for its first clinical program. Launched three years ago, Dicerna has been building a new platform for RNAi work that relies heavily on longer molecules than the ones used by RNAi pioneers like Alnylam and Sirna. The longer molecules improve on the potency,...